Intravitreal Dexamethasone Implant in Patients with Persistent Diabetic Macular Edema

Purpose: To evaluate the effects of a single injection of Ozurdex over 6 months in eyes with persistent diabetic macular edema (DME). Methods: In this retrospective interventional study, 9 patients with decreased visual acuity, as a result of persistent DME, received Ozurdex (intravitreal dexamethasone implant 0.7 mg). Main outcome measures included changes in best-corrected visual acuity (BCVA) and central retinal thickness (CRT). Results: Nine eyes of 9 patients (5 males, 4 females; mean age 58 years) were included in the analysis. The mean duration of DME was 49.9 months (range 24–85). All patients had undergone previous treatments for DME (intravitreal injection of anti-vascular endothelial growth factor, steroids or laser photocoagulation) before entering the study. At baseline, the mean BCVA was 0.74 ± 0.33 logMAR, and the mean CRT was 502 ± 222.16 µm. The mean BCVA was unchanged on the third day (0.74 ± 0.38 logMAR, p = 0.5), improved to 0.62 ± 0.32 logMAR (p = 0.02), 0.59 ± 0.26 logMAR (p = 0.02) and 0.63 ± 0.38 logMAR (p = 0.6) after the first, third and fourth months, respectively, and decreased again to 0.73 ± 0.35 logMAR (p = 0.4) at 6 months. The mean CRT improved to 397 ± 115.31 µm (p = 0.17), 271 ± 99.97 µm (p = 0.007), 325 ± 133.05 µm (p = 0.03) and 462 ± 176.48 µm (p = 0.36) on the third day and after 1, 3 and 4 months of follow-up and then increased again to 537 ± 265.42 µm (p = 0.33) at 6 months. Eight patients needed retreatments in the sixth month. One eye developed a transient intraocular pressure (IOP) increase 1 month after injection, which was successfully managed with topical IOP-lowering medication. Conclusion: In eyes with persistent DME, Ozurdex produces improvement in BCVA and CRT as soon as the first days after the injection. Such improvement is maintained until the fourth month.

[1]  S. Whitcup,et al.  Pharmacokinetics of a sustained-release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes. , 2011, Investigative ophthalmology & visual science.

[2]  C. Lowder,et al.  Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. , 2011, Archives of ophthalmology.

[3]  L. Wheeler,et al.  Treatment of experimental anterior and intermediate uveitis by a dexamethasone intravitreal implant. , 2011, Investigative ophthalmology & visual science.

[4]  H. Tabandeh,et al.  DEXAMETHASONE INTRAVITREAL IMPLANT FOR TREATMENT OF DIABETIC MACULAR EDEMA IN VITRECTOMIZED PATIENTS , 2011, Retina.

[5]  D. Goldstein,et al.  Dexamethasone for ocular inflammation , 2011, Expert opinion on pharmacotherapy.

[6]  Francesco Bandello,et al.  The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. , 2011, Ophthalmology.

[7]  Jane S. Myung,et al.  Treatment of noninfectious posterior uveitis with dexamethasone intravitreal implant , 2010, Clinical ophthalmology.

[8]  Elham Hatef,et al.  Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. , 2010, Ophthalmology.

[9]  Simon P. Harding,et al.  Safety and Efficacy of Ranibizumab in Diabetic Macular Edema (RESOLVE Study) , 2010, Diabetes Care.

[10]  Lloyd Paul Aiello,et al.  Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema , 2010, Ophthalmology.

[11]  M. Blumenkranz,et al.  Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. , 2010, Ophthalmology.

[12]  George A. Williams,et al.  Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. , 2010, Archives of ophthalmology.

[13]  Judy E. Kim,et al.  Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. , 2009, Archives of ophthalmology.

[14]  J. Haller,et al.  EVALUATION OF THE SAFETY AND PERFORMANCE OF AN APPLICATOR FOR A NOVEL INTRAVITREAL DEXAMETHASONE DRUG DELIVERY SYSTEM FOR THE TREATMENT OF MACULAR EDEMA , 2009, Retina.

[15]  K. Eng,et al.  RANDOMIZED CONTROLLED STUDY OF AN INTRAVITREOUS DEXAMETHASONE DRUG DELIVERY SYSTEM IN PATIENTS WITH PERSISTENT MACULAR EDEMA , 2007 .

[16]  George A. Williams,et al.  Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. , 2007, Archives of ophthalmology.

[17]  L. Aiello,et al.  Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. , 1998, Diabetes.

[18]  Hidehiro Ishii,et al.  Vascular Endothelial Growth Factor–Induced Retinal Permeability Is Mediated by Protein Kinase C In Vivo and Suppressed by an Orally Effective β-Isoform–Selective Inhibitor , 1997, Diabetes.

[19]  Robert N. Johnson,et al.  Progressive enlargement of laser scars following grid laser photocoagulation for diffuse diabetic macular edema. , 1991, Archives of ophthalmology.

[20]  J. Vander.  Dexamethasone Intravitreal Implant for Noninfectious Intermediate or Posterior Uveitis , 2012 .

[21]  Jane S. Myung,et al.  Treatment of noninfectious posterior uveitis with dexamethasone intravitreal implant , 2010 .

[22]  T. Mimura,et al.  Association of vitreous inflammatory factors with diabetic macular edema. , 2009, Ophthalmology.

[23]  H. Yamashita,et al.  Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema. , 2002, American journal of ophthalmology.

[24]  PHOTOCOAGULATION FOR DIABETIC MACULAR EDEMA: EARLY TREATMENT DIABETIC RETINOPATHY STUDY REPORT NO. 4 , 1987, International ophthalmology clinics.